Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2R mice
Figure 5
Ex vivo expanded extGLuc+ EBs express high level of eGFP by FACS analyses. Maturation profile and transfection efficiency of nontransfected (as control, top panels) and transfected (bottom panels) EBs at day 9 of HEMA culture identified on the basis of CD36/CD235a and eGFP expression (on the left) and on the basis of morphology (May-Grunwald staining, on the right), magnification 40x. The transfected EBs express great levels of eGFP. The transfection did not alter the morphology of the cells but slightly reduced the expression of the CD235a probably due to interference with the GFP signal. At day 9, in transfected and control cultures the fold increase was 48-fold and 325-fold, respectively, and the viability was 98% in both cases.
